Toward the institutionalization of quantum computing in pharmaceutical research.
Computational drug design
Drug development
Drug discovery
Pharmaceutical industry
Quantum computing
R&D organization
Technology adoption
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
26
07
2021
revised:
13
08
2021
accepted:
15
10
2021
pubmed:
25
10
2021
medline:
21
4
2022
entrez:
24
10
2021
Statut:
ppublish
Résumé
Innovative pharmaceutical companies have started to explore quantum computing (QC). In this article, we provide a collective industry perspective from QC domain leaders at leading pharmaceutical companies. There are immediate nonfinancial benefits in engaging with QC, some likely financial returns in the short term in drug development, manufacturing, and supply chain, and potentially large scientific benefits in drug discovery long term. We discuss the required activities for institutionalizing QC: how to create an understanding of QC among researchers and management, which and how to deploy external resources, and how to identify the problems to be addressed with QC. If (and once) deployable, QC will likely have a similar trajectory to that of computer-aided drug design (CADD) and artificial intelligence (AI) during the 1990s and 2010s, respectively.
Identifiants
pubmed: 34688911
pii: S1359-6446(21)00444-X
doi: 10.1016/j.drudis.2021.10.006
pii:
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
378-383Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.